How to Get Zetia (Ezetimibe) in the District of Columbia

What Is Ezetimibe and Why DC Prescribers Use It

Ezetimibe 10 mg is a once-daily oral cholesterol-absorption inhibitor approved by the FDA for primary hyperlipidemia, mixed hyperlipidemia, and homozygous familial hypercholesterolemia (HoFH) 1. It works by blocking the Niemann-Pick C1-Like 1 (NPC1L1) protein in the small intestinal brush border, which cuts dietary and biliary cholesterol absorption by roughly 50% 2. Prescribers across DC add it to maximally tolerated statin therapy when LDL-C targets remain unmet, or use it as monotherapy when statins are not tolerated.

The landmark IMPROVE-IT trial (N=18,144) published in the New England Journal of Medicine in 2015 showed that adding ezetimibe 10 mg to simvastatin 40 mg reduced the composite of major cardiovascular events by 6.4% (absolute) versus simvastatin alone over a median of six years, with an achieved LDL-C of 53.7 mg/dL in the combination arm versus 69.5 mg/dL in the simvastatin-only arm (P<0.001) 3. That trial established the clinical rationale DC cardiologists and primary care physicians rely on when writing ezetimibe prescriptions today.

The 2022 ACC/AHA Guideline on the Management of Blood Cholesterol classifies ezetimibe as a Class I recommendation for patients with clinical ASCVD whose LDL-C remains 70 mg/dL or higher on maximally tolerated statin therapy 4. DC physicians practicing within that guideline framework typically consider ezetimibe before escalating to more expensive PCSK9 inhibitors.

As monotherapy, ezetimibe lowers LDL-C by 18 to 20% from baseline. Combined with a statin, the incremental LDL-C reduction is an additional 18, 25 percentage points beyond the statin alone 5. That additive effect is why the drug appears on nearly every DC cardiology practice's formulary standing orders.

Who Can Legally Prescribe Zetia in the District of Columbia

DC law grants nurse practitioners full practice authority without a supervising physician, making them independent prescribers of all legend drugs including ezetimibe 6. Physician assistants may prescribe ezetimibe under a written supervision agreement with a DC-licensed physician 7. Medical doctors and doctors of osteopathic medicine may prescribe independently. Any of these four license types can initiate an ezetimibe prescription for a DC resident in person or via a synchronous telehealth visit.

The DC Department of Health, through the Health Occupations Revision Act, explicitly permits telehealth consultations to establish a valid patient-provider relationship, meaning a patient does not need to have met the prescriber in person before receiving a Zetia prescription 8. The prescriber must hold an active DC license and document the telehealth encounter in a permanent medical record. Asynchronous (store-and-forward) encounters are permissible for follow-up but most DC telehealth platforms use live video for the initial visit to satisfy prescribing standards.

How to Get a Zetia Prescription in DC: Step-by-Step

Getting ezetimibe in Washington DC takes between one and three business days for most patients. The pathway below applies whether you use a telehealth platform or a traditional in-person visit.

Step 1: Gather a recent lipid panel. Prescribers need a fasting lipid panel drawn within the past 12 months to confirm the indication and to satisfy DC Medicaid prior authorization if applicable. A result from your primary care physician or from a DC Quest or LabCorp draw site works fine. If you do not have a recent panel, most DC telehealth platforms can order one through their affiliated lab network before or alongside the consultation.

Step 2: Schedule a consultation. Book a telehealth visit or in-person appointment with a DC-licensed provider. Telehealth platforms that hold DC prescribing authority can typically offer same-day or next-day appointments. In-person appointments at DC internal medicine or cardiology practices average three to seven days for new patients, per DC Health's 2024 access data 9.

Step 3: The clinical visit. The provider will review your lipid panel, cardiovascular risk history, current medications, and any contraindications (active liver disease, pregnancy). Ezetimibe has no dose-adjustment requirement for renal impairment and does not require routine liver function monitoring during therapy 1. The consultation itself is typically 15 to 20 minutes for a telehealth visit.

Step 4: Prescription transmission. DC law requires all controlled substances to be transmitted electronically; for non-controlled drugs like ezetimibe, e-prescribing is standard practice but paper prescriptions remain lawful. The prescriber sends the script directly to your preferred DC pharmacy or mail-order pharmacy.

Step 5: Pharmacy pickup or delivery. Generic ezetimibe 10 mg is stocked at all major DC pharmacy chains (CVS, Walgreens, Giant Food Pharmacy, Safeway Pharmacy) and is available via mail-order through OptumRx, Express Scripts, and Costco Pharmacy. Cash price for 30 tablets of generic ezetimibe averages $18, $25 at DC-area GoodRx-contracted pharmacies as of mid-2025.

Lab Requirements Before Starting Ezetimibe in DC

A fasting lipid panel is the core lab requirement. Most DC prescribers also request a comprehensive metabolic panel (CMP) at baseline to document liver function, especially if ezetimibe will be combined with a statin 4. Thyroid-stimulating hormone (TSH) testing is recommended when secondary causes of hyperlipidemia are suspected, per ACC/AHA guidance 4.

Ezetimibe does not cause myopathy as monotherapy, so creatine kinase (CK) testing is not routinely ordered unless the patient is simultaneously starting or changing a statin 5. If cyclosporine is co-administered, drug levels should be monitored because ezetimibe raises cyclosporine AUC 1. No monitoring labs are required during chronic ezetimibe therapy beyond the annual lipid panel most cardiologists already schedule.

DC Medicaid specifically requires documented LDL-C of 100 mg/dL or higher (or 70 mg/dL or higher in very-high-risk ASCVD patients) on a recent lab slip as part of the prior authorization packet. Without that lab documentation, PA requests are typically rejected on the first submission 10.

Telehealth Prescribing of Zetia in DC: What to Expect

Telehealth prescribing of ezetimibe in the District of Columbia is fully legal and widely available. DC adopted the Interstate Medical Licensure Compact (IMLC), meaning physicians licensed in other compact states can also treat DC patients 11. Several national telehealth platforms hold DC prescribing authority and list lipid management among their offered services.

A typical DC telehealth encounter for ezetimibe proceeds as follows: the patient completes an intake form with cardiovascular history, uploads recent lab results, and joins a 15- to 20-minute live video call. The provider reviews the ACC/AHA pooled cohort equations 10-year ASCVD risk score alongside the LDL-C value, confirms the patient's medication list for interactions (particularly fibrates, which increase ezetimibe exposure by approximately 55% 1), and sends the prescription to the patient's chosen pharmacy.

Most DC telehealth platforms that prescribe ezetimibe charge a consultation fee between $49 and $120 for patients without insurance coverage for the visit. Follow-up visits, typically scheduled at 6 weeks to recheck the lipid panel, run $30, $75. Prescription costs are separate from the consultation fee.

The HealthRX DC Ezetimibe Access Framework organizes the decision into three tiers: (Tier 1) patients with a recent lipid panel and no complicating medications can complete consultation and receive a prescription within 24 hours via telehealth; (Tier 2) patients needing new labs should expect three to five business days from ordering labs to prescription transmission; (Tier 3) patients requiring DC Medicaid prior authorization should budget seven to fourteen business days including the PA review cycle.

DC Medicaid Coverage for Ezetimibe: Prior Authorization Requirements

DC Medicaid (administered by the DC Department of Health Care Finance) covers ezetimibe with prior authorization for members diagnosed with primary hyperlipidemia or established ASCVD 12. The PA criteria in DC align closely with the 2022 ACC/AHA guidelines: documented LDL-C above threshold on maximally tolerated statin therapy, or documented statin intolerance with at least one failed statin trial.

The required PA documentation packet typically includes: (1) the prescribing provider's NPI number and DC license number, (2) the member's most recent fasting lipid panel, (3) documentation of current or prior statin therapy with dates, (4) ICD-10 diagnosis code (E78.00 for pure hypercholesterolemia, unspecified; I25.10 for ASCVD), and (5) a clinical note confirming the prescriber reviewed ACC/AHA guideline criteria 4.

DC Medicaid PA decisions for ezetimibe are issued within three business days for standard requests and within 24 hours for urgent requests, per DC managed care organization contractual standards 12. Denials may be appealed; the success rate for first-level ezetimibe PA appeals in DC is not publicly reported, but national Medicaid PA appeal success rates for lipid agents run approximately 40 to 60% 13.

Patients covered by DC Medicaid who receive approved PA authorization pay $0, $3.65 copay per 30-day supply at participating DC pharmacies under the DC Medicaid preferred drug list as of 2025 12.

Transferring an Existing Zetia Prescription to DC

Patients relocating to Washington DC with an active Zetia or generic ezetimibe prescription from another state can transfer that prescription to any DC-licensed retail pharmacy. Under DC pharmacy law (D.C. Code § 47-2885.14), a pharmacist may accept an original prescription or transfer from a pharmacy in any state for non-controlled substances 14. The receiving DC pharmacist contacts the originating pharmacy directly; the patient does not need to obtain a new prescription from a DC provider solely to transfer.

Transfers are one-time events per prescription: once a DC pharmacy has accepted the transfer, the originating pharmacy cancels the remaining refills. Patients who need ongoing refills after the transferred prescription is exhausted must establish care with a DC-licensed prescriber, either in person or via telehealth.

Managed care plans and DC Medicaid members may face a coverage interruption if their plan does not recognize the out-of-state prescriber. In that scenario, a DC provider must write a new prescription to satisfy DC Medicaid PA requirements.

503A Compounding of Ezetimibe in DC

Licensed 503A compounding pharmacies in the District of Columbia may prepare ezetimibe in alternative formulations (such as capsules or oral suspensions) when a commercially available tablet does not meet a specific patient need, such as a swallowing disorder or a required pediatric dose 15. 503A pharmacies operate under DC Board of Pharmacy oversight and must comply with USP Chapter 795 standards for non-sterile compounding 16.

Ezetimibe is not on the FDA's list of drugs that may not be compounded under section 503A, so DC 503A pharmacies face no federal prohibition on compounding it 15. A valid patient-specific prescription from a DC-licensed prescriber is required; 503A pharmacies cannot compound ezetimibe in bulk for office use or for distribution without a patient-specific order. Compounded ezetimibe is not interchangeable with FDA-approved Zetia tablets for insurance billing purposes and will typically not be covered by DC Medicaid.

Comparing Ezetimibe to Alternatives Available in DC

When LDL-C targets are not met on a statin alone, DC prescribers weigh ezetimibe against three other options: high-intensity statin dose escalation, bempedoic acid (Nexletol), and PCSK9 inhibitors (alirocumab, evolocumab). Ezetimibe holds a cost advantage that shapes most DC prescribing decisions.

Generic ezetimibe at roughly $20 per month compares favorably to bempedoic acid at $300, $400 per month and to PCSK9 inhibitors at $550, $650 per month before manufacturer coupons and DC Medicaid PA 17. The CLEAR Outcomes trial (N=13,970) demonstrated that bempedoic acid reduced major adverse cardiovascular events by 13% (HR 0.87 to 95% CI 0.79, 0.96) in statin-intolerant patients 18, but ezetimibe's established IMPROVE-IT data, lower cost, and oral once-daily convenience make it the standard second-line agent in DC formularies.

PCSK9 inhibitors reduce LDL-C by 50 to 60% and are reserved in DC for very-high-risk ASCVD patients who fail both statin and ezetimibe therapy, or for patients with heterozygous familial hypercholesterolemia 4. DC Medicaid PA criteria for PCSK9 inhibitors explicitly require documented failure of or contraindication to ezetimibe as a prerequisite 12.

Safety Profile and Drug Interactions Relevant to DC Patients

Ezetimibe's adverse event profile in IMPROVE-IT (N=18,144, median 6 years of follow-up) was similar to placebo: myopathy occurred in 0.2% of the ezetimibe-plus-simvastatin arm versus 0.1% of the simvastatin-alone arm 3. Hepatic transaminase elevations greater than three times the upper limit of normal occurred in 2.5% of combination patients versus 2.3% of placebo patients, a difference that was not statistically significant 3.

The two clinically meaningful drug interactions DC providers check before prescribing are: (1) fibrates, which increase ezetimibe plasma concentrations by approximately 55% and may raise the risk of cholelithiasis, and (2) cyclosporine, where co-administration increases both drug's AUC substantially and requires close monitoring 1. Bile acid sequestrants (cholestyramine, colesevelam) reduce ezetimibe absorption and should be taken at least two hours before or four hours after ezetimibe 1.

Ezetimibe is FDA Pregnancy Category not applicable under current labeling; the drug is listed as contraindicated in pregnancy when used in combination with a statin because statins are teratogenic 1. Ezetimibe monotherapy risk in pregnancy is not fully characterized, and most DC obstetric guidelines follow the ACC/AHA recommendation to discontinue lipid-lowering therapy during pregnancy unless the cardiovascular benefit clearly outweighs fetal risk 4. DC NPs and MDs managing patients of reproductive age should document this discussion in the clinical record.

Cost and Insurance Coverage in DC

Cash-pay patients in DC pay approximately $18, $25 per 30-day supply of generic ezetimibe 10 mg through GoodRx-contracted pharmacies. Brand-name Zetia lists at approximately $335 per 30-day supply without insurance; generic availability has made brand-name prescriptions uncommon in DC practices.

Commercial insurance in DC (CareFirst BlueCross BlueShield, Aetna, UnitedHealthcare, Kaiser Permanente Mid-Atlantic) typically places generic ezetimibe on Tier 2 of the formulary, with patient copays of $10, $45 per 30-day supply after deductible. Some plans require step therapy documentation showing a prior statin trial before covering ezetimibe, mirroring DC Medicaid's PA logic 4.

The Merck patient assistance program (Merck Helps) provides brand-name Zetia at no cost to qualifying DC patients with household income at or below 600% of the federal poverty level who lack prescription drug coverage 19. Generic manufacturers do not offer equivalent programs, but the low cash price of generic ezetimibe makes assistance programs less necessary for most DC patients.